Experimental Drug Shows Promise in Treating Severe COVID-19
An experimental drug has shown promising results in treating severe COVID-19 patients during the first phase of trials at Tel Aviv's Ichilov Hospital. Developed by BioNTech in Germany, the drug is expected to be made quickly and easily, with no anticipated side effects.
Administered as a simple spray once a day, the drug significantly improved breathing and increased blood oxygen levels in severely ill patients. The drug's creator, Professor Arbar Nadir, expects the full research cycle to be completed by the end of the year. The second phase of trials, involving 100 patients, is set to begin soon. If successful, the drug could be distributed worldwide within a few months, pending approvals. The drug's mechanism of action targets the protein CD24 using exosomes for administration, making it a unique approach in COVID-19 treatment.
The third phase of trials, involving several hundred patients, will follow. If the drug continues to show high efficacy and safety, it could revolutionize the treatment of severe COVID-19 patients. The drug's creator aims to release it as a simple spray that can be used at home, preventing the need for ventilation.
